Trials / Not Yet Recruiting
Not Yet RecruitingNCT06704113
Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients
Analgesic Efficacy of Meloxicam Versus Ibuprofen for Pain Control After Third Molar Extraction in Adult Patients: Randomized Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Universidad Austral de Chile · Academic / Other
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
Third molar extraction is a common dental procedure, offently related with pain and swelling. The purpose of this study is to evaluate if Meloxicam has a better effect relieving pain after the extraction than Ibuprofen, one of the most common pain relieving drugs administered after this procedure.
Detailed description
Summary: Third molar extractions are one of the most common procedures in dental practice. However, pain and swelling as postoperative sequelae are inevitable. Depending on the level of pain, which can range from moderate to severe, this symptomatology can be accompanied with pharmacological treatment, thus generating a less traumatic recovery for the patient. It is currently known that non-steroidal anti-inflammatory drugs (NSAIDs) have proven to be effective for the treatment of mild and moderate postoperative pain. Due to the wide variety of NSAIDs, it is important to know how to choose the most effective option when indicating one therapeutic option over another. Objective: To evaluate the postoperative analgesic effectiveness of meloxicam (7.5 mg) compared to ibuprofen (400 mg) in patients undergoing third molar(s) extraction. Design: Randomized controlled clinical trial, double-masked, designed according to CONSORT guideline requirements.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | meloxicam 7,5mg | Comparison of analgesic efficacy of Meloxicam Vs Ibuprofen |
Timeline
- Start date
- 2024-12-15
- Primary completion
- 2025-01-15
- Completion
- 2025-01-20
- First posted
- 2024-11-25
- Last updated
- 2024-11-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06704113. Inclusion in this directory is not an endorsement.